Kurt Hammond Named Exo Chief Commercial Officer

Exo has appointed Kurt Hammond as chief commercial officer. With more than three decades of experience scaling healthcare software brands, Hammond is now responsible for developing and executing the sales, marketing, partnerships and customer success strategies to drive the commercialization of Exo’s fully integrated ultrasound ecosystem.
 
Hammond most recently served as chief growth officer at eMed Digital Healthcare, where he supervised sales, customer success, product management, marketing, and partnership development functions for a first-of-its-kind point-of-care diagnostic lab platform. Prior to eMed Digital Healthcare, he led six healthcare startups, including Halo Health and Merge Healthcare, to successful exits and has been involved in more than 20 mergers and acquisitions in the healthcare market. After Merge Healthcare was acquired by IBM in 2015, Hammond was named vice president of Global Imaging Sales for IBM Watson Health, eventually being promoted to global vice president of Partnerships and Business Development.
 
“With deep-rooted expertise in healthcare IT, SaaS and artificial intelligence, Kurt is the ideal leader to usher Exo into our next phase of growth. He shares our vision of bringing healthcare outside the constraints of hospital walls and uniquely understands the solutions required to make that a reality,” Exo Co-Founder/CEO Sandeep Akkaraju said. “As Exo expands its medical imaging ecosystem, Kurt’s experience leading health tech companies will be core to our success.”
 
Hammond’s appointment as chief commercial officer occurs at a pivotal period in Exo’s trajectory in delivering simple and accessible medical imaging. The company has developed an end-to-end ultrasound ecosystem to provide caregivers with immediate medical answers at the point of care to improve patient outcomes. That includes launching its Exo Works point-of-care ultrasound (POCUS) workflow solution last year, which streamlines documentation, billing and quality assurance in one platform. Exo has also acquired U.S. Food and Drug Administration-cleared AI capabilities and will be commercializing a new handheld ultrasound. Built on Exo’s proprietary ultrasound technology, this pocket-sized ultrasound device delivers high-performance imaging at a fraction of the cost of cart-based systems.
 
Exo’s ecosystem is being implemented in healthcare institutions nationwide including Henry Ford Health and Sana Kliniken AG, which have partnered with Exo to leverage its platform to lower the barriers to ultrasound access and use, enabling faster diagnoses and treatment across all care settings. Additionally, institutions like West Virginia University’s Medical Center for POCUS are integrating Exo Works into medical school programs to train caregivers on the future of ultrasound.
 
“Exo is the first company I’ve worked with that has dedicated the resources to bring a fully loaded, seamless platform to the healthcare market,” Hammond stated. “The company has solved the technological and workflow issues caregivers experience when using modern point-of-care ultrasound solutions. This is only the beginning of Exo’s journey to disrupt medical imaging and I am proud to join a team so focused on creating a healthier and more equitable world.”
 
Exo is a medical imaging software and device company. The company is on a mission to modernize medical imaging through its high-performance ultrasound platform and artificial intelligence. Exo’s goal is to enable healthcare professionals to make critical, real-time decisions that ultimately improve patient outcomes.